Gregory’s Pediatric Anesthesia
Chapter 11 - References
1. Aird WC. Coagulation. Crit Care Med 2005; 33: S485–7.
2. Levi M. Platelets. Crit Care Med 2005; 33: S523–5.
3. Wright IS. Nomenclature of blood clotting factors: four factors, their characterization and
international number. JAMA 1959; 170: 325–8.
4. Davie EW, Ratnoff OD. Waterfall sequence for intrinsic blood clotting. Science 1964; 145: 1310–
12.
5. Macfarlane RG. An enzyme cascade in the blood clotting mechanism, and its function as a
biochemical amplifier. Nature 1964; 202, 498–9.
6. Hoffman M, Monroe DM. Coagulation 2006: a modern view of hemostasis. Hematol Oncol Clin
North Am 2007; 21: 1–11.
7. Tanaka KA, Key NS, Levy JH. Blood coagulation: hemostasis and thrombin regulation. Anesth
Analg 2009; 108: 1433–46.
8. Adams, GL, Manson RJ, Turner I, Sindram D, Lawson JH. The balance of thrombosis and
hemorrhage in surgery. Hematol Oncol Clin North Am 2007; 21: 13–24.
9. Mann KG. Thrombin formation. Chest 2003; 124: 4S–10S.
10. Andrew M, Paes B, Johnston M. Development of the hemostatic system in the neonate and
young infant. Am J Pediatr Hematol Oncol 1990; 12: 95–104.
11. Bleyer WA, Hakami N, Shepard TH. The development of hemostasis in the human fetus and
newborn infant. J Pediatr 1971; 79: 838–53.
12. Andrew M, Paes B, Milner R et al. Development of the human coagulation system in the healthy
premature infant. Blood 1988; 72: 1651–7.
13. Andrew M, Paes B, Milner R et al. Development of the human coagulation system in the fullterm infant. Blood 1987; 70: 165–72.
14. Sell EJ, Corrigan JJ Jr. Platelet counts, fibrinogen concentrations, and factor V and factor VIII
levels in healthy infants according to gestational age. J Pediatr 1973; 82: 1028–32.
15. Corrigan JJ Jr, Sleeth JJ, Jeter M, Lox CD. Newborn’s fibrinolytic mechanism: components and
plasmin generation. Am J Hematol 1989; 32: 273–8.
16. Von Felten A, Straub PW. Coagulation studies of cord blood, with special reference to “fetal
fibrinogen”. Thromb Diath Haemorrh 1969; 22: 273–80.
17. Witt I, Müller H, Künzer W. Evidence for the existence of foetal fibrinogen. Thromb Diath
Haemorrh 1969; 22: 101–9.
18. Miller BE, Tosone SR, Guzzetta NA, Miller JL, Brosius KK. Fibrinogen in children undergoing
cardiac surgery: is it effective? Anesth Analg 2004; 99: 1341–6.
19. Reverdiau-Moalic P, Delahousse B, Body G, Bardos P, Leroy J, Gruel Y. Evolution of blood
coagulation activators and inhibitors in the healthy human fetus. Blood 1996; 88: 900–6.
20. Gordon EM, Ratnoff OD, Saito H, Gross S, Jones PK. Studies on some coagulation factors
(Hageman factor, plasma prekallikrein, and high molecular weight kininogen) in the normal
newborn. Am J Pediatr Hematol Oncol 1980; 2: 213–16.
21. Andrew M, Bhogal M, Karpatkin M. Factors XI and XII and prekallikrein in sick and healthy
premature infants. New Engl J Med 1981; 305: 1130–3.
22. Andrew M. Anticoagulation and thrombolysis in children. Texas Heart Inst J 1992; 19: 168–77.
23. Mull MM, Hathaway WE. Altered platelet function in newborns. Pediat Res 1970; 4: 229–37.
24. Hathaway W, Corrigan J. Report of Scientific and Standardization Subcommittee on Neonatal
Hemostasis: normal coagulation data for fetuses and newborn infants. Thromb Haemost 1991: 65:
323–5.
25. Miller BE, Bailey JM, Mancuso TJ et al. Functional maturity of the coagulation system in
children: an evaluation using thrombelastography. Anesth Analg 1997; 84: 745–8.
26. Andrew M, Vegh P, Johnston M, Bowker J, Ofosu F, Mitchell L. Maturation of the hemostatic
system during childhood. Blood 1992; 80: 1998–2005.
27. Sié P, Steib A. Central laboratory and point of care assessment of perioperative hemostasis.
Can J Anesth 2006; 53: S12–S20.
28. Duke WW. The relation of blood platelets to hemorrhagic disease: description of a method for
determining the bleeding time and coagulation time and report of three cases of hemorrhagic
disease relieved by transfusion. JAMA 1910; 55: 1185–92.
29. Peterson P, Hayes TE, Arkin CF et al. The preoperative bleeding time test lacks clinical benefit:
College of American Pathologists’ and American Society of Clinical Pathologists’ position article.
Arch Surg 1998; 133: 134–9.
30. Harrison P, Mumford A. Screening tests of platelet function: update on their appropriate uses for
diagnostic testing. Semin Thromb Hemost 2009; 35: 150–7.
31. Lind SE. The bleeding time does not predict surgical bleeding. Blood 1991; 77: 2547–52.
32. Jilma B. Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet
dysfunction. J Lab Clin Med 2001; 138: 152–63.
33. Carcao MD, Blanchette VS, Dean JA et al. The Platelet Function Analyzer (PFA-100®): a novel
in vitro system for evaluation of primary haemostasis in children. Br J Haematol 1998; 101: 70–3.
34. Seegmiller A, Sarode R. Laboratory evaluation of platelet function. Hematol Oncol Clin North
Am 2007; 21: 731–42.
35. Hayward CPM, Harrison P, Cattaneo M et al. Platelet function analyzer (PFA)–100® closure
time in the evaluation of platelet disorders and platelet function. J Thromb Haemost 2006; 4: 312–9.
36. Brown JE, Bosak JO. An ELISA test for the binding of von Willebrand antigen to collagen.
Thromb Res 1986; 43: 303–11.
37. Gill JC. Diagnosis and treatment of von Willebrand disease. Hematol Oncol Clin North Am 2004;
18: 1277–99.
38. Rochon AG, Shore-Lesserson L. Coagulation monitoring. Anesthesiol Clin 2006; 24: 839–56.
39. Feldman MD, McCrae KR. Clinical coagulation laboratory evaluation of hemostasis in the
perioperative period. In: Lake CL, Moore RA (eds) Blood: Hemostasis, Transfusion, and Alternatives
in the Perioperative Period. New York: Raven Press, 1995, pp. 153–78.
40. Kopeć M, Teisseyre E, Dudek-Wojciechowska G et al. Studies on the “double D” fragment from
stabilized bovine fibrin. Thromb Res 1973; 2: 283–92.
41. Gaffney PJ. F.D.P. (letter). Lancet 1972; ii: 1422.
42. Gaffney PJ, Edgell T, Creighton-Kempsford LJ, Wheeler S, Tarelli E. Fibrin degradation product
(FnDP) assays: analysis of standardization issues and target antigens in plasma. Br J Haematol
1995; 90: 187–94.
43. Mallett SV, Cox DJA. Thrombelastography. Br J Anaesth 1992; 69: 307–13.
44. Miller BE, Guzzetta NA, Tosone SR, Levy JH. Rapid evaluation of coagulopathies after
cardiopulmonary bypass in children using modified thromboelastography. Anesth Analg 2000; 90:
1324–30.
45. Kettner SC, Panzer OP, Kozek SA et al. Use of abciximab-modified thrombelastography in
patients undergoing cardiac surgery. Anesth Analg 1999; 89: 580–4.
46. Kozek-Langenecker SA. Perioperative coagulation monitoring. Best Pract Res Clin Anaesthesiol
2010; 24: 27–40.
47. Gabriel DA, Carr M, Roberts HR. Monitoring coagulation and the clinical effects of recombinant
Factor VIIa. Semin Hematol 2004; 41(Suppl 1): 20–4.
48. Midathada MV, Mehta P, Waner M et al. Recombinant Factor VIIa in the treatment of bleeding.
Am J Clin Pathol 2004; 121: 124–37.
49. Greilich PE, Alving BM, O’Neill KL, Chang AS, Reid TJ. A modified thromboelastographic
method for monitoring c7E3 Fab in heparinized patients. Anesth Analg 1997; 84: 31–8.
50. Tanaka KA, Szlam F, Sun HY, Taketomi T, Levy JH. Thrombin generation assay and
viscoelastic coagulation monitors demonstrate differences in the mode of thrombin inhibition
between unfractionated heparin and bivalirudin. Anesth Analg 2007; 105: 933–9.
51. Kang YG, Martin DJ, Marquez J et al. Intraoperative changes in blood coagulation and
thrombelastographic monitoring in liver transplantation. Anesth Analg 1985; 64: 888–96.
52. Tuman KJ, Spiess BD, McCarthy RJ, Ivankovich AD. Comparison of viscoelastic measures of
coagulation after cardiopulmonary bypass. Anesth Analg 1989; 69: 69–75.
53. Shore-Lesserson L, Manspeizer HE, DePerio M, Francis S, Vela-Cantos F, Ergin MA.
Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac
surgery. Anesth Analg 1999; 88: 312–19.
54. Royston D, von Kier S. Reduced haemostatic factor transfusion using heparinase-modified
thrombelastography during cardiopulmonary bypass. Br J Anaesth 2001; 86: 575–8.
55. Ganter MT, Hofer CK. Coagulation monitoring: current techniques and clinical use of
viscoelastic point-of-care coagulation devices. Anesth Analg 2008; 106: 1366–75.
56.
Zwack
GC,
Derkay
CS.
The
utility
of
preoperative
hemostatic
assessment
in
adenotonsillectomy. Int J Pediatr Otorhinolaryngol 1997; 39: 67–76.
57. Eckman MH, Erban JK, Singh SK, Kao GS. Screening for the risk for bleeding or thrombosis.
Ann Intern Med 2003; 138: W15–W24.
58. Shaw PH, Reynolds S, Gunawardena S, Krishnamurti L, Ritchey AK. The prevalence of
bleeding disorders among healthy pediatric patients with abnormal preprocedural coagulation
studies. J Pediatr Hematol Oncol 2008; 30: 135–41.
59. Suchman AL, Mushlin AI. How well does the activated partial thromboplastin time predict
postoperative hemorrhage? JAMA 1986; 256: 750–3.
60. Manning SC, Beste D, McBride T, Goldberg A. An assessment of preoperative coagulation
screening for tonsillectomy and adenoidectomy. Int J Pediatr Otorhinolaryngol 1987; 13: 237–44.
61. Krishna P, Lee D. Post-tonsillectomy bleeding: a meta-analysis. Laryngoscope 2001; 111:
1358–61.
62. Gabriel P, Mazoit X, Ecoffey C. Relationship between clinical history, coagulation tests, and
perioperative bleeding during tonsillectomies in pediatrics. J Clin Anesth 2000; 12: 288–91.
63. Burk CD, Miller L, Handler SD et al. Preoperative history and coagulation screening in children
undergoing tonsillectomy. Pediatrics 1992; 89: 691–5.
64. Kang J, Brodsky L, Danziger I, Volk M, Stanievich J. Coagulation profile as a predictor for posttonsillectomy and adenoidectomy (T + A) hemorrhage. Int J Pediatr Otorhinolaryngol 1994; 28: 157–
65. Rohrer MJ, Michelotti MC, Nahrwold DL. A prospective evaluation of the efficacy of preoperative
coagulation testing. Ann Surg 1988; 208: 554–7.
66. Kaplan EB, Sheiner LB, Boeckmann AJ et al. The usefulness of preoperative laboratory
screening. JAMA 1985; 253: 3576–81.
67. Howells RC II, Wax MK, Ramadan HH. Value of preoperative prothrombin time/partial
thromboplastin time as a predictor of postoperative hemorrhage in pediatric patients undergoing
tonsillectomy. Otolaryngol Head Neck Surg 1997; 117: 628–32.
68. Asaf T, Reuveni H, Yermiahu T et al. The need for routine pre-operative coagulation screening
tests (prothrombin time PT/partial thromboplastin time PTT) for healthy children undergoing elective
tonsillectomy and/or adenoidectomy. Int J Pediatr Otorhinolaryngol 2001; 61: 217–22.
69. American Society of Anesthesiologists Task Force on Preanesthesia Evaluation. Practice
advisory for preanesthesia evaluation. Anesthesiology 2002; 96: 485–96.
70. American Academy of
Otolaryngology-Head
and Neck
Surgery.
Clinical Indicators
Compendium. Alexandria, VA: American Academy of Otolaryngology-Head and Neck Surgery,
1999.
71. Borzotta AP, Keeling MM. Value of the preoperative history as an indicator of hemostatic
disorders. Ann Surg 1984; 200: 648–52.
72. Rapaport SI. Preoperative hemostatic evaluation: which tests, if any? Blood 1983; 61: 229–31.
73. Ng KFJ, Lai KW, Tsang SF. Value of preoperative coagulation tests: reappraisal of major
noncardiac surgery. World J Surg 2002; 26: 515–20.
74. Williams GD, Bratton SL, Riley EC, Ramamoorthy C. Coagulation tests during cardiopulmonary
bypass correlate with blood loss in children undergoing cardiac surgery. J Cardiothorac Vasc
Anesth 1999; 13: 398–404.
75. Zimmerman TS, Ruggeri ZM. von Willebrand disease. Hum Pathol 1987; 18: 140–52.
76. Ruggeri ZM, Zimmerman TS. von Willebrand factor and von Willebrand disease. Blood 1987;
70: 895–904.
77. Abildgaard CF, Suzuki Z, Harrison J, Jefcoat K, Zimmerman TS. Serial studies in von
Willebrand’s disease: variability versus “variants”. Blood 1980; 56: 712–16.
78. Dunn AL, Abshire TC. Recent advances in the management of the child who has hemophilia.
Hematol Oncol Clin North Am 2004; 18: 1249–76.
79. Rodriguez NI, Hoots WK. Advances in hemophilia: experimental aspects and therapy. Pediatr
Clin North Am 2008; 55: 357–6.
80. Astermark J. Basic aspects of inhibitors to factors VIII and IX and the influence of non-genetic
risk factors. Haemophilia 2006; 12: 8–14.
81. Hoffman M, Monroe DM III. The action of high-dose factor VIIa (FVIIa) in a cell-based model of
hemostasis. Disease-a-Month 2003; 49: 14–21.
82. Dietrich JE, Yee DL. Thrombophilic conditions in the adolescent: the gynecologic impact. Obstet
Gynecol Clin North Am 2009; 36: 163–75.
83. Coppens M, Kaandorp SP, Middeldorp S. Inherited thrombophilias. Obstet Gynecol Clin North
Am 2006; 33: 357–74.
84. Journeycake JM, Manco-Johnson MJ. Thrombosis during infancy and childhood: what we know
and what we do not know. Hematol Oncol Clin North Am 2004; 18: 1315–38.
85. Kenet G, Nowak-Göttl U. Fetal and neonatal thrombophilia. Obstet Gynecol Clin North Am 2006;
33: 457–66.
86. Edstrom CS, Christensen RD. Evaluation and treatment of thrombosis in the neonatal intensive
care unit. Clin Perinatol 2000; 27: 623–41.
87. Favaloro EJ, McDonald D, LippiG. Laboratory investigation of thrombophilia: the good, the bad,
and the ugly. Semin Thromb Hemost 2009; 35: 695–710.
88. Nuss R, Hays T, Chudgar U, Manco-Johnson M. Antiphospholipid antibodies and coagulation
regulatory protein abnormalities in children with pulmonary emboli. J Pediatr Hematol Oncol 1997;
19: 202–7.
89. Goldenberg NA, Bernard TJ. Venous thromboembolism in children. Pediatr Clin North Am 2008;
55: 305–22.
90. Uddin DE, Dickson LG, Brodine CE. Screening of military recruits for hemoglobin variants.
JAMA 1974; 227: 1405–7.
91. Allison AC. Protection afforded by sickle-cell trait against subtertian malarial infection. BMJ
1954; 4857: 290–4.
92. Fixler J, Styles L. Sickle cell disease. Pediatr Clin North Am 2002; 49: 1193–210.
93. Firth PG, Head CA. Sickle cell disease and anesthesia. Anesthesiology 2004; 101: 766–85.
94. Benjamin LT, Dampier CD, Jacox A et al. Guidelines for the management of acute and chronic
pain in sickle-cell disease. American Pain Society. APS Clinical Practice Series 1999; 1: xi.
95. Mehta SR, Afenyi-Annan A, Byrns PJ, Lottenberg R. Opportunities to improve outcomes in
sickle cell disease. Am Fam Physician 2006; 74: 303–10.
96. Vichinsky EP, Haberkern CM, Neumayr L et al. A comparison of conservative and aggressive
transfusion regimens in the perioperative management of sickle cell disease. N Engl J Med 1995;
333: 206–13.
97. National Institutes of Health. The Management of Sickle Cell Disease, 4th edn. NIH Publication
02–2177. Bethesda, MD: National Institutes of Health, 2002, pp. 149–51.
98. Griffin TC, Buchanan GR. Elective surgery in children with sickle cell disease without
preoperative blood transfusion. J Pediatr Surg 1993; 28: 681–5.
99. Vichinsky EP, Luban NLC, Wright E et al. Prospective RBC phenotype matching in a stroke
prevention trial in sickle cell anemia: a multicenter transfusion trial. Transfusion 2001; 41: 1086–92.
100. Adu-Gyamfi Y, Sankarankutty M, Marwa S. Use of a tourniquet in patients with sickle-cell
disease. Can J Anaesth 1993; 40: 24–7.
101. Oginni LM, Rufai MB. How safe is tourniquet use in sickle-cell disease? Afr J Med Med Sci
1996; 25: 3–6.
102. Al-Ghamdi AA. Bilateral total knee replacement with tourniquets in a homozygous sickle cell
patient. Anesth Analg 2004; 98: 543–4.
103. Shulman G, McQuitty C, Vertrees RA, Conti VR. Acute normovolemic red cell exchange for
cardiopulmonary bypass in sickle cell disease. Ann Thorac Surg 1998; 65: 1444–6.
104. Bhatt K, Cherian S, Agarwal R, Jose S, Cherian KM. Perioperative management of sickle cell
disease in paediatric cardiac surgery. Anaesth Intens Care 2007; 35: 792–5.
105. Stanford School of Medicine. http://bloodcenter.stanford.edu/bcinfo/AboutBlood.html (accessed
5 March 2010).
106. American Society of Anesthesiologists Committee on Transfusion Medicine. Questions and
Answers about Blood Management, 4th edn. 2008. www.ASAhq.org (accessed 26 February 2010).
107. Fasano R, Luban NLC. Blood component therapy. Pediatr Clin North Am 2008; 55: 421–45.
108. American Association of Blood Banks. Circular of information for the use of human blood and
blood components, 2009. www.aabb.org/resources (accessed 26 February 2010).
109. Allen MB. Component preparation and storage. In: Hillyer CD, Silberstein LE, Ness PM,
Anderson KC, Roback JD (eds) Blood Banking and Transfusion Medicine: Basic Principles and
Practice. Philadelphia: Churchill Livingstone, 2003, pp. 121–36.
110. Ferraris VA, Ferraris SP, Saha SP et al. Perioperative blood transfusion and blood
conservation in cardiac surgery: the Society of Thoracic Surgeons and the Society of
Cardiovascular Anesthesiologists clinical practice guideline. Ann Thorac Surg 2007; 83: S27–S86.
111. Manno CS, Hedberg KW, Kim HC et al. Comparison of the hemostatic effects of fresh whole
blood, stored whole blood, and components after open heart surgery in children. Blood 1991; 77:
930–6.
112. Baldini M, Costea N, Dameshek W. The viability of stored human platelets. Blood 1960; 16:
1669–92.
113. Luban NLC, Wong ECC. Irradiated products and washed/volume reduced products. In: Hillyer
CD, Silberstein LE, Ness PM, Anderson KC, Roback JD (eds) Blood Banking and Transfusion
Medicine: Basic Principles and Practice. Philadelphia: Churchill Livingstone, 2003, pp. 253–64.
114. Goodnough LT. Risks of blood transfusion. Crit Care Med 2003; 31: S678–86.
115. American Society of Anesthesiologists Task Force on Perioperative Blood Transfusion and
Adjuvant Therapies. Practice guidelines for perioperative blood transfusion and adjuvant therapies.
Anesthesiology 2006; 105: 198–208.
116. Bucur SZ, Hillyer CD. Cryoprecipitate and related products. In: Hillyer CD, Silberstein LE, Ness
PM, Anderson KC, Roback JD (eds) Blood Banking and Transfusion Medicine: Basic Principles and
Practice. Philadelphia: Churchill Livingstone, 2003, pp. 161–5.
117. Perrotta PL, Pisciotto PT, Snyder EL. Platelets and related products. In: Hillyer CD, Silberstein
LE, Ness PM et al (eds.) Blood Banking and Transfusion Medicine: Basic Principles and Practice,
Philadelphia: Churchill Livingstone, pp. 181–205.
118. Erber WN. Massive blood transfusion in the elective surgical setting. Transfus Apher Sci 2002;
27: 83–92.
119. Spahn DR, Casutt M. Eliminating blood transfusions: new aspects and perspectives.
Anesthesiology 2000; 93: 242–55.
120. Laverdiére C, Gauvin F, Hébert PC et al. Survey on transfusion practices of pediatric
intensivists. Pediatr Crit Care Med 2002; 3: 335–40.
121. Armano R, Gauvin F, Ducruet T, Lacroix J. Determinants of red blood cell transfusions in a
pediatric critical care unit: a prospective, descriptive epidemiological study. Crit Care Med 2005; 33:
2637–44.
122. Hébert PC, Wells G, Blajchman MA et al. A multicenter, randomized, controlled clinical trial of
transfusion requirements in critical care. N Engl J Med 1999; 340: 409–17.
123. Lacroix J, Hébert PC, Hutchinson JS et al. Transfusion strategies for patients in pediatric
intensive care units. N Engl J Med 2007; 356: 1609–19.
124. Isbister JP. Decision making in perioperative transfusion. Transfus Apher Sci 2002; 27: 19–28.
125. Kirpalani H, Whyte RK, Andersen C et al. The premature infants in need of transfusion (PINT)
study: a randomized, controlled trial of a restrictive (low) versus liberal (high) transfusion threshold
for extremely low birth weight infants. J Pediatr 2006; 149: 301–7.
126. Bell EF, Strauss RG, Widness JA et al. Randomized trial of liberal versus restrictive guidelines
for red blood cell transfusion in preterm infants. Pediatrics 2005; 115: 1685–91.
127. Guay J, de Moerloose P, Lasne D. Minimizing perioperative blood loss and transfusions in
children. Can J Anesth 2006; 53: S59–67.
128. Morris KP, Naqvi N, Davies P, Smith M, Lee PW. A new formula for blood transfusion volume
in the critically ill. Arch Dis Child 2005; 90: 724–8.
129. Gajic O, Dzik WH, Toy P. Fresh frozen plasma and platelet transfusion for nonbleeding
patients in the intensive care unit: benefit or harm? Crit Care Med 2006; 34 (Suppl 5): S170–3.
130. Sadler JE. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura.
Blood 2008; 112: 11–18.
131. Harker LA, Malpass TW, Branson HE, Hessel EA 2nd, Slichter SJ. Mechanism of abnormal
bleeding in patients undergoing cardiopulmonary bypass: acquired transient platelet dysfunction
associated with selective α-granule release. Blood 1980; 56: 824–34.
132. Perkins JG, Cap AP, Weiss BM, Reid TJ, Bolan CD. Massive transfusion and nonsurgical
hemostatic agents. Crit Care Med 2008; 36: S325–39.
133. Shaz BH, Dente CJ, Harris RS, MacLeod JB, Hillyer CD. Transfusion management of trauma
patients. Anesth Analg 2009; 108: 1760–8.
134. Hardy JF, de Moerloose P, Samama CM, Members of the Groupe d'Intérêt en Hémostase
Périopératoire. Massive transfusion and coagulopathy: pathophysiology and implications for clinical
management. Can J Anesth 2006; 53: S40–58.
135. Miller RD. Massive blood transfusions: the impact of Vietnam military data on modern civilian
transfusion medicine. Anesthesiology 2009; 110: 1412–16.
136. Rossaint R, Duranteau J, Stahel PF, Spahn DR. Nonsurgical treatment of major bleeding.
Anesthesiol Clin 2007; 25: 35–48.
137. Spahn DR, Rossaint R. Coagulopathy and blood component transfusion in trauma. Br J
Anaesth 2005; 95: 130–9.
138. Ho AMH, Karmakar MK, Dion PW. Are we giving enough coagulation factors during major
trauma resuscitation? Am J Surg 2005; 190: 479–84.
139. Malone DL, Hess JR, Fingerhut A. Massive transfusion practices around the globe and a
suggestion for a common massive transfusion protocol. J Trauma 2006; 60: S91–6.
140. Holcomb JB, Hess JR. Early massive trauma transfusion: state of the art. J Trauma 2006; 60:
S1–2.
141. Dente CJ, Shaz BH, Nicholas JM et al. Improvements in early mortality and coagulopathy are
sustained better in patients with blunt trauma after institution of a massive transfusion protocol in a
civilian level I trauma center. J Trauma 2009; 66: 1616–24.
142. Dodd RY. Current risk for transfusion transmitted infections. Curr Opin Hematol 2007; 14: 671–
6.
143. Adamson JW. New blood, old blood, or no blood? N Engl J Med 2008; 358: 1295–6.
144. Hillyer CD, Josephson CD, Blajchman MA, Vostal JG, Epstein JS, Goodman JL. Bacterial
contamination of blood components: risks, strategies, and regulation. joint ASH and AABB
Educational Session in Transfusion Medicine. Hematology Am Soc Hematol Educ Program 2003:
575–89.
145. Stramer SL, Glynn SA, Kleinman SH et al. Detection of HIV-1 and HCV infections among
antibody-negative blood donors by nucleic acid-amplification testing. N Engl J Med 2004; 351: 760–
8.
146. Hendrickson JE, Hillyer CD. Noninfectious serious hazards of transfusion. Anesth Analg 2009;
108: 759–69.
147. Atler HJ, Klein HG. The hazards of blood transfusion in historical perspective. Blood 2008; 112:
2617–26.
148. Busch MP, Kleinman SH, Nemo GJ. Current and emerging infectious risks of blood
transfusions. JAMA 2003; 289: 959–62.
149. Pealer LN, Marfin AA, Petersen LR et al. Transmission of West Nile Virus through blood
transfusion in the United States in 2002. N Engl J Med 2003; 349: 1236–45.
150. Morbidity and Mortality Weekly Report. Detection of West Nile Virus in blood donations –
United States, 2003. MMWR 2003; 52: 769–72.
151. Blajchman MA, Vamvakas EC. The continuing risk of transfusion-transmitted infections. N Engl
J Med 2006; 355: 1303–5.
152. Toy P, Popovsky MA, Abraham E et al. Transfusion-related acute lung injury: definition and
review. Crit Care Med 2005; 33: 721–6.
153. Triulzi DJ. Transfusion-related acute lung injury: current concepts for the clinician. Anesth
Analg 2009; 108: 770–6.
154. Silliman CC, Ambruso DR, Boshkov LK. Transfusion-related acute lung injury. Blood 2005;
105: 2266–73.
155. British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines for
the use of platelet transfusions. Br J Haematol 2003; 122: 10–23.
156. Vamvakas EC, Blajchman MA. Transfusion-related immunomodulation (TRIM): an update.
Blood Rev 2007; 21: 327–48.
157. Miller RD. Complications of massive blood transfusions. Anesthesiology 1973; 39: 82–93.
158. Ho J, Sibbald WJ, Chin-Yee IH. Effects of storage on efficacy of red cell transfusion: when is it
not safe? Crit Care Med 2003; 31: S687–97.
159. Goodnough LT, Shander A. Blood management. Arch Pathol Lab Med 2007; 131: 695–701.
160. Shimpo H, Mizumoto T, Onoda K, Yuasa H, Yada I. Erythropoietin in pediatric cardiac surgery:
clinical efficacy and effective dose. Chest 1997; 111: 1565–70.
161. Shaddy RE, Bullock EA, Tani LY, Orsmond GS, Hunter DD, Christensen RD. Epoetin alfa
therapy in infants awaiting heart transplantation. Arch Pediatr Adolesc Med 1995; 149: 322–5.
162. Meneghini L, Zadra N, Aneloni V, Metrangolo S, Faggin R, Giusti F. Erythropoietin therapy and
acute preoperative normovolaemic haemodilution in infants undergoing craniosynostosis surgery.
Paediatr Anaesth 2003; 13: 392–6.
163. Sonzogni V, Crupi G, Poma R et al. Erythropoietin therapy and preoperative autologous blood
donation in children undergoing open heart surgery. Br J Anaesth 2001; 87: 429–34.
164. Komai H, Naito Y, Okamura Y, Fujiwara K, Suzuki H, Uemura S. Preliminary study of
autologous blood predonation in pediatric open-heart surgery: impact of advance infusion of
recombinant human erythropoietin. Pediatr Cardiol 2005; 26: 50–5.
165. Goodnough LT, Monk TG, Andriole GL. Erythropoietin therapy. N Engl J Med 1997; 336: 933–
8.
166. Murto KTT, Splinter WM. Perioperative autologous blood donation in children. Transfus Sci
1999; 21: 41–62.
167. Masuda M, Kawachi Y, Inaba S et al. Preoperative autologous blood donations in pediatric
cardiac surgery. Ann Thorac Surg 1995; 60: 1694–7.
168. Fukahara K, Murakami A, Ueda T et al. Scheduled autologous blood donation at the time of
cardiac catheterization in infants and children. J Thorac Cardiovasc Surg 1997; 114: 504–5.
169. Monk TG. Acute normovolemic hemodilution. Anesthesiol Clin North Am 2005; 23: 271–81.
170. Shander A, Perelman S. The long and winding road of acute normovolemic hemodilution.
Transfusion 2006; 46: 1075–9.
171. Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl
J Med 2006; 354: 353–65.
172. Karkouti K, Beattie WS, Dattilo KM et al. A propensity score case-control comparison of
aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery. Transfusion 2006; 46: 327–
38.
173. Mangano DT, Miao Y, Vuylsteke A et al. Mortality associated with aprotinin during 5 years
following coronary artery bypass graft surgery. JAMA 2007; 297: 471–9.
174. Fergusson DA, Hébert PC, Mazer CD et al. A comparison of aprotinin and lysine analogues in
high-risk cardiac surgery. N Engl J Med 2008; 358: 2319–31.
175. Backer CL, Kelle AM, Stewart RD et al. Aprotinin is safe in pediatric patients undergoing
cardiac surgery. J Thorac Cardiovasc Surg 2007; 134: 1421–6.
176. Székely A, Sápi E, Breuer T et al. Aprotinin and renal dysfunction after pediatric cardiac
surgery. Pediatr Anaesth 2008; 18: 151–9.
177. Guzzetta NA, Evans FM, Rosenberg ES et al. The impact of aprotinin on postoperative renal
dysfunction in neonates undergoing cardiopulmonary bypass: a retrospective analysis. Anesth
Analg 2009; 108: 448–55.
178. Manrique A, Jooste EH, Kuch BA et al. The association of renal dysfunction and the use of
aprotinin in patients undergoing congenital cardiac surgery requiring cardiopulmonary bypass.
Anesth Analg 2009; 109: 45–52.
179. Verstraete M. Clinical application of inhibitors of fibrinolysis. Drugs 1985; 29: 236–61.
180. Hardy JF, Desroches J. Natural and synthetic antifibrinolytics in cardiac surgery. Can J
Anaesth 1992; 39: 353–65.
181. McClure PD, Izsak J. The use of epsilon-aminocaproic acid to reduce bleeding during cardiac
bypass in children with congenital heart disease. Anesthesiology 1974; 40: 604–8.
182. Zonis Z, Seear M, Reichert C, Sett S, Allen C. The effect of preoperative tranexamic acid on
blood loss after cardiac operations in children. J Thorac Cardiovasc Surg 1996; 111: 982–7.
183. Chauhan S, Das SN, Bisoi A, Kale S, Kiran U. Comparison of epsilon aminocaproic acid and
tranexamic acid in pediatric cardiac surgery. J Cardiothorac Vasc Anesth 2004; 18: 141–3.
184. Reid RW, Zimmerman AA, Laussen PC, Mayer JE, Gorlin JB, Burrows FA. The efficacy of
tranexamic acid versus placebo in decreasing blood loss in pediatric patients undergoing repeat
cardiac surgery. Anesth Analg 1997; 84: 990–6.
185. Neilipovitz DT, Murto K, Hall L, Barrowman NJ, Splinter WM. A randomized trial of tranexamic
acid to reduce blood transfusion for scoliosis surgery. Anesth Analg 2001; 93: 82–7.
186. Thompson GH, Florentino-Pineda I, Poe-Kochert C. The role of Amicar in decreasing
perioperative blood loss in idiopathic scoliosis. Spine 2005; 30: S94–9.
187. Sethna NF, Zurakowski D, Brustowicz RM, Bacsik J, Sullivan LJ, Shapiro F. Tranexamic acid
reduces intraoperative blood loss in pediatric patients undergoing scoliosis surgery. Anesthesiology
2005; 102: 727–32.
188. Kang Y, Lewis JH, Navalgund A et al. Epsilon-aminocaproic acid for treatment of fibrinolysis
during liver transplantation. Anesthesiology 1987; 66: 766–73.
189. Boylan JF, Klinck JR, Sandler AN et al. Tranexamic acid reduces blood loss, transfusion
requirements, and coagulation factor use in primary orthotopic liver transplantation. Anesthesiology
1996; 85: 1043–8.
190. Zohar E, Ellis M, Ifrach N, Stern A, Sapir O, Fredman B. The postoperative blood-sparing
efficacy of oral versus intravenous tranexamic acid after total knee replacement. Anesth Analg
2004; 99: 1679–83.
191. Cid J, Lozano M. Tranexamic acid reduces allogeneic red cell transfusions in patients
undergoing total knee arthroplasty: results of a meta-analysis of randomized controlled trials.
Transfusion 2005; 45: 1302–7.
192. Henry DA, Carless PA, Moxey AJ et al. Anti-fibrinolytic use for minimizing perioperative
allogeneic blood transfusion (review). Cochrane Database Syst 2007; 4: CD001886.
193. Martin K, Wiesner G, Breuer T, Lange R, Tassani P. The risks of aprotinin and tranexamic acid
in cardiac surgery: a one-year follow-up of 1188 consecutive patients. Anesth Analg 2008; 107:
1783–90.
194. Murkin JM, Falter F, Granton J, Young B, Burt C, Chu M. High-dose tranexamic acid is
associated with nonischemic clinical seizures in cardiac surgical patients. Anesth Analg 2010; 110:
350–3.
195. Lisman T, de Groot PHG. Mechanism of action of recombinant factor VIIa. J Thromb Haemost
2003; 1: 1138–9.
196. Hedner U. Dosing with recombinant factor VIIa based on current evidence. Semin Hematol
2004; 41: 35–9.
197.
NovoSeven®RT.
Package
insert.
Bagsvaerd,
Denmark:
Novo
Nordisk
A/S.
www.us.novoseven.com/pdfs/PI_novosevenrt.pdf (accessed 21 April 2010).
198. Ghorashian S, Hunt BJ. “Off-licence” use of recombinant activated factor VII. Blood Rev 2004;
18: 245–59.
199. Spahn DR, Tucci MA, Makris M. Is recombinant FVIIa the magic bullet in the treatment of
major bleeding? Br J Anaesth 2005; 94: 553–5.
200. Lodge JPA, Jonas S, Jones RM et al. Efficacy and safety of repeated perioperative doses of
recombinant factor VIIa in liver transplantation. Liver Transpl 2005; 11: 973–9.
201. Guzzetta NA, Huch S, Fernandez JD, Tosone SR, Miller BE. Use of recombinant factor VIIa for
uncontrolled bleeding in neonates after cardiopulmonary bypass. Pediatr Anaesth 2009; 19: 364–
70.
202. Warren OJ, Rogers PLB, Watret AL et al. Defining the role of recombinant activated factor VIIa
in pediatric cardiac surgery: where should we go from here? Pediatr Crit Care Med 2009; 10: 572–
82.
203. Dutton RP, McCunn M, Hyder M et al. Factor VIIa for correction of traumatic coagulopathy. J
Trauma 2004; 57: 709–19.
204. Boffard KD, Riou B, Warren B et al. Recombinant factor VIIa as adjunctive therapy for bleeding
control in severely injured trauma patients: two parallel randomized, placebo-controlled, doubleblind clinical trials. J Trauma 2005; 59: 8–18.